WMT
67
4
REGN
71
6
FFIV
58
2
PNR
63
3
TAP
45
-5
TDC
70
2
EQT
57
3
ETN
83
4
NWS
79
15
EIX
58
2
MCD
47
-15
SPG
55
5
INTC
35
3
SNA
60
5
WMB
67
3
MOS
22
3
CMS
64
2
T
44
2
XEL
58
3
UAL
56
2
WMT
67
4
REGN
71
6
FFIV
58
2
PNR
63
3
TAP
45
-5
TDC
70
2
EQT
57
3
ETN
83
4
NWS
79
15
EIX
58
2
MCD
47
-15
SPG
55
5
INTC
35
3
SNA
60
5
WMB
67
3
MOS
22
3
CMS
64
2
T
44
2
XEL
58
3
UAL
56
2
Financhill
Back

ProPhase Labs 10K Form

Buy
54

PRPH
ProPhase Labs

Last Price:
5.47
Seasonality Move:
10.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRPH News And Ratings

See the #1 stock for the next 7 days that we like better than PRPH

PRPH Financial Statistics

Sales & Book Value

Annual Sales: $44.38M
Cash Flow: $-1.52M
Price / Cash Flow: 0
Annual Sales: $2.74
Price / Book: 2.09

Profitability

EPS (TTM): -0.98000
Net Income (TTM): $-16.78M
Gross Margin: $16.24M
Return on Equity: -29.07%
Return on Assets: -18.33%

ProPhase Labs Earnings Forecast

Key ProPhase Labs Financial Ratios

  • The Gross Profit Margin over the past 27 years for PRPH is 36.59%.
  • The Selling, General & Administrative Expenses for PRPH have been equal to 77.74% of Gross Profit Margin.
  • The Research & Development expenses have been 3.19% of Revenue.
  • The Interest Expense is -7.60% of Operating Income.
  • The Net Earning history of PRPH is -37.81% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

ProPhase Labs Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PRPH
CUSIP: 74345W
Website: prophaselabs.com

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 2.28
Quick Ratio: 1.97

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 11.29

PRPH Technical Analysis vs Fundamental Analysis

Buy
54
ProPhase Labs (PRPH) is a Buy

Is ProPhase Labs a Buy or a Sell?

  • ProPhase Labs stock is rated a Buy
    The current ProPhase Labs [PRPH] share price is $5.42. The Score for PRPH is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.